2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2850

Changes in Urinary Biomarker Levels Can Predict Treatment Responses in Lupus Nephritis
Abstract Number: 2851

An Antigen Microarray to Rule-out Systemic Lupus Erythematosus, the SLE-Key® Rule-out Test, Performs Well As an Aid in Clinical Practice
Abstract Number: 2852

Long Term Prognosis of Lupus Nephritis in the Afro-Caribbean Population of Martinique with Free Access to Healthcare
Abstract Number: 2853

Neutrophilia in Systemic Lupus Erythematosus As a Potential Indicator of Disease Activity
Abstract Number: 2854

Laboratory and Demographic Longitudinal Profile of a Large Cohort of Individuals Presenting with the ANA Nuclear Dense Fine Speckled Immunofluorescence Pattern
Abstract Number: 2855

The Long-Term Clinical Outcomes of Lupus Nephritis
Abstract Number: 2856

Serum C5a Is Elevated in Lupus Nephritis and in Neuropsychiatric Systemic Lupus Erythematosus through Different Mechanisms
Abstract Number: 2857

Results from a Phase 0 Longitudinal Clinical Trial in Cutaneous Lupus Erythematosus: Analysis of the Type I IFN Signature in the Skin and Blood and Its Relationship with Disease Activity Scores and Autoantibody Profiles
Abstract Number: 2858

Urinary PF4 and E-Selectin As Novel Biomarkers for Disease Activity and Renal Damage in Lupus Nephritis
Abstract Number: 2859

Health-Related Interference of Social Activities and Suicidal Ideation in Systemic Lupus Erythematosus: Georgians Organized Against Lupus Cohort
Abstract Number: 2860

Exercise Significantly Improves Cardiorespiratory Fitness and Reduces Disease-Related Fatigue without Adverse Effects on Disease Activity in Systemic Lupus Erythematosus: a Systematic Review with Meta-Analysis
Abstract Number: 2861

Proportions of Circulating Follicular Helper T Cells and Complement Levels, White Blood Cell Counts, and Skin Manifestations in Patients with Active Systemic Lupus Erythematosus
Abstract Number: 2862

Whole Blood Phenotyping and Innate and Adaptive Stimulation Reveal Unique Differences in Granulocytes and Innate Pathways of African American SLE Patients with Variable Disease Activity
Abstract Number: 2863

High Frequency of Terminally Differentiated CD8+ T Cells Characterize Systemic Lupus Erythematosus Patients with Renal Involvement
Abstract Number: 2864

Identifying Dysregulated and Co-Dysregulated Markers in Systemic Lupus Erythematosus Using Multi-Modal Biomarker Data from a Large Pre-Clinical Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].